List view / Grid view
6 February 2015 | By Genticel
Genticel announces that data obtained with ProCervix, its lead therapeutic vaccine, will be presented in the EUROGIN (EUropean Research Organisation on Genital Infection and Neoplasia) 2015 Congress taking place at the FIBES II Conference and Exhibition Centre in Seville, Spain on February 4 – 7...
5 February 2015 | By The Institute of Cancer Research
Pioneering prostate cancer drug abiraterone significantly extends the lives of men with advanced prostate cancer if given before chemotherapy, the results of a major phase III clinical trial have shown...
5 February 2015 | By TxCell
TxCell, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, reports its revenues as of December 31, 2014 and updates on forthcoming milestones...
5 February 2015 | By Rigontec GmbH
Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announces the appointment of Dr. Christian Schetter as CEO...
5 February 2015 | By The Institute of Cancer Research
A worldwide study of the DNA of 100,000 women has discovered two new genetic variants associated with an increased risk of breast cancer...
5 February 2015 | By MRC Technology
MRC Technology has appointed Dr Edward Bliss in the new role of General Counsel and Company Secretary...
4 February 2015 | By Frost & Sullivan
Ongoing research aims to develop oncologic imaging technologies that diagnose cancer at the cellular level before the disease manifests, finds Frost & Sullivan...
3 February 2015 | By Motif Bio
Motif Bio plc is seeking to raise at least £4 million through a placing of new ordinary shares and admission to trading on AIM...
3 February 2015 | By Innovative Medicines Initiative (IMI)
Two years after the start of the Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) programme, the first patient has been enrolled into a Phase 2 trial sponsored by MedImmune, the global biologics research and development arm of AstraZeneca. The trial with MEDI4893 is among mechanically ventilated intubated…
2 February 2015 | By ABIVAX
ABIVAX today announced that enrollment has been initiated and the first HIV positive patient dosed in a Phase IIa clinical trial of ABX464...
2 February 2015 | By Imec
The CARDIS project will develop and validate an early-stage cardio vascular disease detection platform using integrated silicon photonics...
30 January 2015 | By TxCell
TxCell SA announces its financial calendar for 2015...
29 January 2015 | By Medical Research Council
Minister for Life Sciences George Freeman announced a further £13.7 million investment in stratified medicine collaborations funded by the Medical Research Council (MRC)...
29 January 2015 | By TxCell
Milestone payment triggered by first patient enrolment in the phase IIb clinical trial for refractory Crohn’s disease...
28 January 2015 | By GlobalData
While current treatments for Alzheimer’s Disease are only able to ease symptoms temporarily, tau-based vaccines may offer a new and more effective way to treat AD in the early course of the disease, says an analyst with research and consulting firm GlobalData...
